Siemens Healthineers company Varian has completed enrollment for its FAST-02 (Flash Radiotherapy for the Treatment of Symptomatic Bone Metastases in the Thorax) clinical trial.
The study targets thoracic bone metastases and "represents a significant step toward bringing this investigational radiotherapy treatment into clinical practice," according to the firm. It is being conducted at Cincinnati Children's Hospital/UC Health Proton Therapy Center in Ohio and includes 10 patients; it builds upon findings from the company's FAST-01 trial, which evaluated clinical workflow feasibility of Flash therapy and treatment-related side effects for participants with bone metastases in the extremities, Varian said.
FAST-02's principal investigator is John Perentesis, MD, director of the Cancer and Blood Disease Institute at Cincinnati Children's Hospital. Its co-lead investigator is Emily Daugherty, MD, associate professor of radiation oncology at the University of Cincinnati Cancer Center.
![A 53-year-old patient (patient number four) with a recurrent pituitary adenoma with extension of a cystic component of disease to the medial temporal lobe apparent on MRI (contoured in blue), and extension of disease to the left sphenoid bone and orbital apex apparent on [68Ga]Ga-DOTA-TATE (contoured in yellow).](https://img.auntminnie.com/mindful/smg/workspaces/default/uploads/2026/04/pituitary-tumor.QGsEnyB4bU.jpg?auto=format%2Ccompress&dpr=2&fit=crop&h=167&q=70&w=250)
